Corline Biomedical AB
CLBIO
Rank in Stocks
#24322
Corline Biomedical AB is a company dedicated to the creation, production, and... Corline Biomedical AB is a company dedicated to the creation, production, and distribution of heparin-based solutions. These solutions are specifically engineered to enhance outcomes in kidney transplantation, cellular therapies, and regenerative medicine. At the heart of their product line is the proprietary Corline Heparin Conjugate (CHC) technology, a unique heparin conjugate that can function as a standalone pharmaceutical compound. The company's diverse portfolio includes Renaparin, aimed at treating end-stage renal failure; Cytoparin, a cell therapy designed for patients with type 1 diabetes; the CHC compound itself for addressing soft tissue injuries; and a variety of medical devices, such as CHS, a coronary stent. Established in 1991, Corline Biomedical AB operates from its headquarters in Uppsala, Sweden.
Share Price
$1.31
Last synced: 2026-11-09
Market Cap
$34.13M
Change (1 day)
-0.25%
Change (1 year)
-35.33%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Corline Biomedical AB (CLBIO)
Category
Healthcare
Operating Margin for Corline Biomedical AB (CLBIO)
Operating Margin as of November 2026 TTM: -97.70%
According to Corline Biomedical AB's latest financial reports, its current operating margin (TTM) is -97.70%. At the end of 2025 the company had an operating margin of -185.70%.
Operating Margin history for Corline Biomedical AB from 2012 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | -97.70% | -47.39% |
| 2025 | -185.70% | -21.64% |
| 2024 | -236.99% | 3,219.19% |
| 2023 | -7.14% | -172.19% |
| 2022 | 9.89% | -110.11% |
| 2021 | -97.83% | -50.38% |
| 2020 | -197.16% | -78.01% |
| 2019 | -896.62% | 106.33% |
| 2018 | -434.55% | -64.50% |
| 2017 | -1,223.98% | 122.05% |
| 2016 | -551.21% | 0.71% |
| 2015 | -547.33% | 268.25% |
| 2014 | -148.63% | 9.93% |
| 2013 | -135.21% | 873.43% |
| 2012 | -13.89% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 38.59% | -100.39% |
US
|
|
| -149.01% | -98.47% |
US
|
|
| 25.57% | -100.26% |
AU
|
|
| 31.23% | -100.32% |
BE
|
|
| 29.35% | -100.30% |
NL
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about Corline Biomedical AB's operating margin
What is Corline Biomedical AB's operating margin?
Corline Biomedical AB's operating margin is -97.70%, as of Nov 2026.
What was Corline Biomedical AB's operating margin in 2025?
In 2025, Corline Biomedical AB's operating margin was -185.70%, compared with -236.99% in 2024.
How has Corline Biomedical AB's operating margin changed since 2020?
From 2020 to 2025, Corline Biomedical AB's operating margin was highest in 2022 (9.89%) and lowest in 2024 (-236.99%).
How does Corline Biomedical AB's operating margin compare with similar companies?
Corline Biomedical AB's operating margin (-97.70%) is higher than that of 1 of the 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with 38.59%.